🇺🇸 FDA
Patent

US 7618630

Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

granted A61KA61K38/00A61P

Quick answer

US patent 7618630 (Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists) held by The Board of Regents of the University of Texas System expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K38/00, A61P, A61P35/00